Treatment of focal dystonia

Current Treatment Options in Neurology

Volumn 14, Issue 3, 2012, Pages 213-229

  Batla, Amit ^a   Stamelou, Maria ^a   Bhatia, Kailash P ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

Anticholinergics; Botulinum toxin; Deep brain stimulation; Focal dystonia; Treatment

Indexed keywords

AMANTADINE; AMPHETAMINE; BACLOFEN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CLOZAPINE; HALOPERIDOL; LEVODOPA; LISURIDE; PLACEBO; RISPERIDONE; TETRABENAZINE; TIAPRIDE; TRIHEXYPHENIDYL;

ACCESS TO INFORMATION; AIRWAY OBSTRUCTION; APHASIA; BLEPHAROSPASM; BLURRED VISION; BODY POSTURE; BRAIN DEPTH STIMULATION; BRONCHOSPASM; CERVICAL DYSTONIA; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DEPRESSION; DIPLOPIA; DIZZINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRY EYE; DYSARTHRIA; DYSPHAGIA; ECCHYMOSIS; EPIGLOTTITIS; FATIGUE; FLU LIKE SYNDROME; FOCAL DYSTONIA; FOCAL HAND DYSTONIA; HALLUCINATION; HEADACHE; HEMATOMA; HEMIPARESIS; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE PAIN; INTERNET; LACRIMATION; LAGOPHTHALMOS; MEDICAL DECISION MAKING; MEMORY DISORDER; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); MUSCLE SPASM; MUSCLE WEAKNESS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; NECK WEAKNESS; NEUROSURGERY; OROMANDIBULAR DYSTONIA; OUTCOME ASSESSMENT; PARKINSONISM; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT SELECTION; POSTOPERATIVE INFECTION; PTOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK BENEFIT ANALYSIS; SEDATION; SELECTIVE PERIPHERAL DENERVATION; SIDE EFFECT; SPASMODIC DYSPHONIA; SUPPORT GROUP; SYSTEMATIC REVIEW (TOPIC); TACHYPNEA; TORONTO WESTERN SPASMODIC TORTICOLLIS RATING SCALE; TREATMENT PLANNING; TREATMENT RESPONSE; URINE RETENTION; VOCAL CORD DISORDER; VOCAL CORD EDEMA; XEROSTOMIA;

EID: 84865681986     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0169-6     Document Type: Review

References (88)

1. Fahn S, Bressman S, Marsden CD. Classification of dystonia. Adv Neurol. 1998;78:1-10.
2. Jankovic J. Dystonic disorders. In: Tolosa JJ, editor. Parkinson's disease and movement disorders. 5th ed. Philadelphia: Williams and Wilkins; 2007. p. 321-47.
3. Jankovic J. Treatment of dystonia. Lancet Neurol. 2006;5:864-72. (Pubitemid 44715821)
4. Montal M. Botulinum neurotoxin: A marvel of protein design. Annu Rev Biochem. 2010;79:591- 617.
5. Simpson DM, Blitzer A, Brashear A, Comella C, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008;70(19):1699-706. (Pubitemid 351644138)
6. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011;18(1):5-18 These guidelines provide a comprehensive overview of the treatment options and evidence-based recommendations for generalized and focal dystonia.
7. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: Report of an EFNS/MDS-ES Task Force. Eur J Neurol. 2006;13(5):433-44. (Pubitemid 43823355)
8. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD003633.
9. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type A versus anticholinergics for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD004312.
10. Costa J, Espírito-Santo C, Borges A, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD004315.
11. Costa J, Borges A, Espírito-Santo C, Ferreira J, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2005;1:CD004314.
12. Lew MF, Adornato BT, Duane DD, et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology. 1997;49(3):701-7. (Pubitemid 27428008)
13. Brashear A, Lew MF, Dykstra DD, et al. Safety and efficacy of NeuroBloc (Botulinum toxin type B) in type A-responsive cervical dystonia. Neurology. 1999;53(7):1439-46. (Pubitemid 29491934)
14. BrinMF, LewMF, Adler CH, et al. Safety and efficacy of NeuroBloc (Botulinumtoxin type B) in type A-resistant cervical dystonia. Neurology. 1999;53(7):1431-8. (Pubitemid 29491933)
15. Comella CL, Jankovic J, Shannon KM, Dystonia Study Group, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423-9. (Pubitemid 41552774)
16. Pappert EJ, Germanson T, Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naïve patients with cervical dystonia: Randomized, double-blind, non inferiority trial. Mov Disord. 2008;23(4):510-7.
17. Poewe W, Schelosky L, Kleedorfer B, et al. Treatment of spasmodic torticollis with local injections of botulinum toxin. One-year follow-up in 37 patients. J Neurol. 1992;239(1):21-5.
18. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: Results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005;20(7):783-91. (Pubitemid 41227144)
19. Benecke R, Jost WH, Kanovsky P, et al. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology. 2005;64 (11):1949-51. (Pubitemid 40800714)
20. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: A prospective, randomized, double-blind controlled trial. Neurology. 1996;46(4):1066-72. (Pubitemid 26134654)
21. Greene P, Kang U, Fahn S, et al. Double-blind, placebo- controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology. 1990;40:1213-8. (Pubitemid 20244977)
22. Marchetti A, Magar R, Findley L, et al. Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: The REAL DOSE study. Mov Disord. 2005;20 (8):937-44. (Pubitemid 41419507)
23. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64(1):6-12. (Pubitemid 28156530)
24. Edwards M, Quinn N, Bhatia K. Dystonia. In: Edwards M, Quinn N, Bhatia K, editors. Oxford specialist handbook: Parkinson's disease and other movement disorders. Oxford: Oxford University Press; 2008. p. 202-7.
25. Allergan. BOTOX® Prescribing Information [online]. Available at: Http://www.allergan.com/assets/pdf/botox-pi.pdf
26. Burbaud P, Ducerf C, Cugy E, et al. Botulinum toxin treatment in neurological practice: How much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258(9):1670-5. This study has evaluated cost-effectiveness of botulinum toxins in clinics and provides a review of the financial impact of the use of BoNT in neurology practice.
27. Comella CL. The treatment of cervical dystonia with botulinum toxins. J Neural Transm. 2008;115 (4):579-83.
28. Jankovic J, Leder S, Warner D, et al. Cervical dystonia: Clinical findings and associated movement disorders. Neurology. 1991;41(7):1088-91.
29. Jankovic J, Vuong KD, Ahsan J. Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology. 2003;60(7):1186-8. (Pubitemid 36418786)
30. Lawrence I, Moy R. An evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type A. Aesthet Surg J. 2009;29(6):S66-71. Though tested for a nondystonic condition, this study of neutralizing antibody testing in patients with the current form of toxin provides a better insight into the matter of testing neutralizing antibody.
31. Skogseid IM, Ramm-Pettersen J, Volkmann J, et al. Good long-term efficacy of pallidal stimulation in cervical dystonia: A prospective, observer-blinded study. Eur J Neurol. 2011. doi:10.1111/j.1468-1331.03591.x. This is a recent study assessing long-term efficacy of DBS in CD in a blinded form.
32. Kiss ZH, Doig-Beyaert K, Eliasziw M, et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Functional and Stereotactic Section of the Canadian Neurosurgical Society; Canadian Movement Disorders Group. Brain. 2007;130(11):2879-86.
33. Pretto TE, Dalvi A, Kang UJ, et al. A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg. 2008;109(3):405-9.
34. Hung SW, Hamani C, Lozano AM, et al. Long-term outcome of bilateral pallidal deep brain stimulation for primary cervical dystonia. Neurology. 2007;68 (6):457-9. (Pubitemid 46208751)
35. Cacciola F, Farah JO, Eldridge PR, et al. Bilateral deep brain stimulation for cervical dystonia: Long-term outcome in a series of 10 patients. Neurosurgery. 2010;67(4):957-63. This is a study of 10 patients of bilateral DBS for CD with long-term follow-up.
36. Tagliati M, Krack P, Volkmann J, et al. Long-term management of DBS in dystonia: Response to stimulation, adverse events, battery changes, and special considerations. Mov Disord. 2011;26(1):S54-62. This is a useful review of evidence and technical issues associated with DBS use.
37. Jeong SG, Lee MK, Kang JY, et al. Pallidal deep brain stimulation in primary cervical dystonia with phasic type: Clinical outcome and postoperative course. J Korean Neurosurg Soc. 2009;46(4):346-50. This is a study on DBS in CD with prospective long-term measurement of response and outcome.
38. Yianni J, Green AL, McIntosh E, et al. The costs and benefits of deep brain stimulation surgery for patients with dystonia: An initial exploration. Neuromodulation. 2005;8(3):155-61. (Pubitemid 41129936)
39. Bertrand CM. Selective peripheral denervation for spasmodic torticollis: Surgical technique, results, and observations in 260 cases. Surg Neurol. 1993;40 (2):96-103. (Pubitemid 23209275)
40. Chen X, Ma A, Liang J, et al. Selective denervation and resection of cervical muscles in the treatment of spasmodic torticollis: Long-term follow-up results in 207 cases. Stereotact Funct Neurosurg. 2000;75(2- 3):96-102. (Pubitemid 33151572)
41. Münchau A, Palmer JD, Dressler D, et al. Prospective study of selective peripheral denervation for botulinum- toxin resistant patients with cervical dystonia. Brain. 2001;124(4):769-83. (Pubitemid 32303835)
42. National Institute for Clinical Excellence. Interventional Procedure Consultation Document Selective peripheral denervation for cervical dystonia www. nice.org.uk/nicemedia/pdf/ip/IPG080guidance.pdf.
43. Burke RE, Fahn S. Double-blind evaluation of trihexyphenidyl in dystonia. Adv Neurol. 1983;37:189- 92.
44. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: A double-blind crossover study. Ann Neurol. 1982;11:41-7. (Pubitemid 12209517)
45. Gilbert GJ. The medical treatment of spasmodic torticollis. Arch Neurol. 1972;27:503-6.
46. West HH. Treatment of spasmodic torticollis with amantadine: A double blind study. Neurology. 1977;27:198-9. (Pubitemid 8044331)
47. Shaw KM, Hunter KR, Stren GM. Medical treatment of spasmodic Torticollis. Lancet. 1972;1(7765):1399.
48. Ansari KA, Webster D, Manning N. Spasmodic torticollis and L-Dopa: Results of therapeutic trial in six patients. Neurology. 1972;22:672-4.
49. Myerson A, Loman J. Amphetamine sulfate in treatment of spasmodic torticollis. Arch Neurol Psychiatry. 1942;48:823-8.
50. Jantunen J, Kaste M, Iivanainen M, et al. Bromocriptine treatment of spasmodic torticollis: A double blind crossover study. Arch Neurol. 1979;36:449-50. (Pubitemid 9166653)
51. Truong D, Comella C, Fernandez HH, Dysport Benign Essential Blepharospasm Study Group, et al. Efficacy and safety of purified botulinum toxin type A (Dysport) for the treatment of benign essential blepharospasm: A randomized, placebo-controlled, phase II trial. Parkinsonism Relat Disord. 2008;14 (5):407-14.
52. Jankovic J, Comella C, Hanschmann A, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial. Mov Disord. 2011;26(8):1521-8. This is a randomized control trial of Xeomin in treatment of blepharospasm, the first and largest trial of BoNT in blepharospasm.
53. Wabbels B, Reichel G, Fulford-Smith A, et al. Doubleblind, randomised, parallel group pilot study comparing two botulinum toxin type A products for the treatment of blepharospasm. J Neural Transm. 2011;118(2):233-9. This study compares Dysport and Botox preparations for use in blepharospasm.
54. Jankovic J, Orman J. Botulinum A toxin for cranial cervical dystonia: A double-blind, placebo-controlled study. Neurology. 1987;37:616-23. (Pubitemid 17057937)
55. Nussgens Z, Roggenkamper P. Comparison of two botulinum-toxin preparations in the treatment of essential blepharospasm. Graefes Arch Clin Exp Ophthalmol. 1997;235:197-9. (Pubitemid 27326086)
56. Sampaio C, Ferreira JJ, Simoes F, et al. DYSBOT: A single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A - Dysport and Botox - assuming a ratio of 4:1. Mov Disord. 1997;12:1013-8. (Pubitemid 27496782)
57. Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm. 2006;113:303-12. (Pubitemid 43201097)
58. Yomtoob DE, Dewan MA, Lee MS, et al. Comparison of pain scores with 30-gauge and 32-gauge needles for periocular botulinum toxin type A injections. Ophthalmic Plast Reconstr Surg. 2009;25(5):376-7. This study assessed the impact of using a smaller needle for BoNT injection in blepharospasm.
59. Boyle MH, McGwin Jr G, Flanagan CE, et al. High versus low concentration botulinum toxin A for benign essential blepharospasm: Does dilution make a difference? Ophthalmic Plast Reconstr Surg. 2009;25 (2):81-4. This study assessed the impact of using lower concentration of toxin for BoNT injection in blepharospasm.
60. Reese R, Gruber D, Schoenecker T, et al. Long-term clinical outcome in meige syndrome treated with internal pallidum deep brain stimulation. Mov Disord. 2011;26(4):691-8. This is a study of DBS in Meige's syndrome that includes cases of OMD and blepharospasm.
61. Brin MF. Oromandibular dystonia: Treatment of 96 patients with botulinum toxin type A. In: Jankovic J, Hallett M, editors. Therapy with Botulinum Toxin. New York: Marcel Dekker; 1994. p. 429-35.
62. Blitzer A, Brin MF, Greene PE, et al. Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol. 1989;98:93-7. (Pubitemid 19057384)
63. Hermanowicz N, Truong DD. Treatment of oromandibular dystonia with botulinum toxin. Laryngoscope. 1991;101:1216-8.
64. Van den Bergh P, Francart J, Mourin S, et al. Five-year experience in the treatment of focal movement disorders with low-dose Dysport botulinum toxin. Muscle Nerve. 1995;18:720-9.
65. Jankovic J, Orman J. Botulinum A toxin for cranialcervical dystonia: A double-blind, placebo-controlled study. Neurology. 1987;37:616-23. (Pubitemid 17057937)
66. Tan EK, Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: Long-term follow-up. Neurology. 1999;53:2102-7.
67. Bhidayasiri R, Cardoso F, Truong DD. Botulinum toxin in blepharospasm and oromandibular dystonia: Comparing different botulinum toxin preparations. Eur J Neurol. 2006;13(1):21-9.
68. Hallett M, Benecke R, Blitzer A, et al. Treatment of focal dystonias with botulinum neurotoxin. Toxicon. 2009;54(5):628-33. This is an evidence-based review of BoNT use in focal dystonia with personal recommendations from the authors.
69. Greene P, Shale H, Fahn S. Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs. Mov Disord. 1988;3:46-60.
70. Klawans HL, Tanner CM. Cholinergic pharmacology of blepharospasm with oromandibular dystonia (Meige's syndrome). Adv Neurol. 1988;49:443-50.
71. Ludlow CL. Spasmodic dysphonia: A laryngeal control disorder specific to speech. J Neurosci. 2011;31 (3):793-7. This is a review of clinical features and pathophysiology of spasmodic dysphonia.
72. Watts CC, Whurr R, Nye C. Botulinum toxin injections for the treatment of spasmodic dysphonia. Cochrane Database Syst Rev. 2004:CD004327.
73. Watts CR, Nye C, Whurr R. Botulinumtoxin for treating spasmodic dysphonia (laryngeal dystonia): A systematic Cochrane review. Clin Rehabil. 2006;20(2):112-22. (Pubitemid 43379870)
74. Boutsen F, CannitoMP, TaylorM, et al. Botox treatment in adductor spasmodic dysphonia: A meta-analysis. J Speech Lang Hear Res. 2002;45(3):469-81. (Pubitemid 34596316)
75. Whurr R, Nye C, Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: A review of 22 studies. Int J Lang Commun Disord. 1998;33:327-9. (Pubitemid 28459128)
76. Troung DD, Rontal M, Rolnick M, et al. Doubleblind controlled study of botulinum toxin in adductor spasmodic dysphonia. Laryngoscope. 1991;101:630-4.
77. Wong DL, Adams SG, Irish JC, et al. Effect of neuromuscular activity on the response to botulinum toxin injections in spasmodic dysphonia. J Otolaryngol. 1995;24:209-16.
78. Bielamowicz S, Squire S, Bidus K, et al. Assessment of posterior cricoarytenoid botulinum toxin injections in patients with abductor spasmodic dysphonia. Ann Otol Rhinol Laryngol. 2001;110:406-12. (Pubitemid 32433850)
79. Sulica L, Blitzer A, Brin MF, et al. Botulinum toxin management of adductor spasmodic dysphonia after failed recurrent laryngeal nerve section. Ann Otol Rhinol Laryngol. 2003;112(6):499-505. (Pubitemid 36712704)
80. Kruisdijk JJ, Koelman JH, Ongerboer de Visser BW, et al. Botulinum toxin for writer's cramp: A randomised, placebo-controlled trial and 1-year follow-up. J Neurol Neurosurg Psychiatry. 2007;78:264-70. (Pubitemid 46579664)
81. Yoshimura DM, Aminoff MJ, Olney RK. Botulinum toxin therapy for limb dystonias. Neurology. 1992;42:627-30.
82. Tsui JK, Bhatt M, Calne S, Calne DB. Botulinum toxin in the treatment of writer's cramp: A double-blind study. Neurology. 1993;43:183-5. (Pubitemid 23035378)
83. Cole R, Hallett M, Cohen LG. Double-blind trial of botulinum toxin for treatment of focal hand dystonia. Mov Disord. 1995;10:466-71.
84. Marion MH, Afors K, Sheehy MP. Problems of treating writer's cramp with botulinum toxin injections: Results from 10 years of experience. Rev Neurol (Paris). 2003;159:923-7. (Pubitemid 37221458)
85. Molloy FM, Shill HA, Kaelin-Lang A, et al. Accuracy of muscle localization without EMG: Implications for treatment of limb dystonia. Neurology. 2002;58:805-7. (Pubitemid 34211562)
86. Geenen C, Consky E, Ashby P. Localizing muscles for botulinum toxin treatment of focal hand dystonia. Can J Neurol Sci. 1996;23:194-7. (Pubitemid 26302746)
87. Chen R, Karp BI, Goldstein SR, et al. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp. Mov Disord. 1999;14:307-12. (Pubitemid 30011849)
88. Fukaya C, Katayama Y, Kano T, et al. Thalamic deep brain stimulation for writer's cramp. J Neurosurg. 2007;107(5):977-82. (Pubitemid 350255212)